MedTrace Logo

A Phase 1 Study of KHN702 Tablets in Healthy Subjects

NCT07044960 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2025-07-01

No results posted yet for this study

Summary

This study is a single-center, randomized, double-blind, placebo-controlled study divided into a Single Ascending Dose (SAD) stage and a Multiple Ascending Dose (MAD) phase. The primary objective is to evaluate the safety and tolerability of KHN702 tablets in Chinese healthy volunteers（HVs).

Conditions

  • Healthy

Interventions

DRUG

KHN702 tablet or placebo

Subject will receive a single KHN702 tablet or matching placebo orally in fasted state.

DRUG

KHN702 tablet or placebo

All participants will receive KHN702 tablet or matching placebo orally once a day for 7 days in fasted state.

Sponsors & Collaborators

  • Chengdu Kanghong Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-21
Primary Completion
2026-04-01
Completion
2026-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07044960 on ClinicalTrials.gov